Unknown

Dataset Information

0

Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.


ABSTRACT: Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study investigated the effect of VELCADE in combination with a low-dose tPA on aged rats after embolic stroke.Male Wistar rats at the age of 18 to 20 months were treated with VELCADE (0.2 mg/kg) alone, a low-dose tPA (5 mg/kg) alone, combination of VELCADE and tPA, or saline 2 hours after embolic middle cerebral artery occlusion. To test the contribution of endothelial nitric oxide synthase to VELCADE-mediated neuroprotection, endothelial nitric oxide synthase knockout and wild-type mice were treated with VELCADE (0.5 mg/kg) 2 hours after embolic stroke.Treatment with VELCADE significantly reduced infarct volume, whereas tPA alone did not reduce infarct volume and aggravated blood-brain barrier disruption in aged rats compared with saline-treated rats. However, the combination treatment significantly enhanced the reduction of infarct volume, which was associated with an increase in endothelial nitric oxide synthase activity compared with saline-treated rats. Additionally, the combination treatment promoted thrombolysis and did not increase the incidence of hemorrhage transformation. VELCADE significantly reduced lesion volume in wild-type mice but failed to significantly reduce lesion volume in endothelial nitric oxide synthase knockout mice.Treatment with VELCADE exerts a neuroprotective effect in aged rats after stroke. The combination of VELCADE with the low-dose tPA further amplifies the neuroprotective effect. Endothelial nitric oxide synthase at least partly contributes to VELCADE-mediated neuroprotection after stroke.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC2860668 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.

Zhang Li L   Zhang Zheng Gang ZG   Buller Ben B   Jiang James J   Jiang Yanting Y   Zhao Danping D   Liu Xianshuang X   Morris Dan D   Chopp Michael M  

Stroke 20100304 5


<h4>Background and purpose</h4>Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study investigated the effect of VELCADE in combination with a low-dose tPA on aged rats after embolic stroke.<h4>Methods</h4>Male Wistar rats at the age of 18 to 20 months were treated with VELCADE (  ...[more]

Similar Datasets

| S-EPMC3966939 | biostudies-literature
| S-EPMC3632085 | biostudies-literature
| S-EPMC3912312 | biostudies-literature
| S-EPMC522796 | biostudies-literature
| S-EPMC3170947 | biostudies-literature
| S-EPMC3412625 | biostudies-literature
| S-EPMC3621146 | biostudies-literature
| S-EPMC6629476 | biostudies-literature
| S-EPMC3938250 | biostudies-literature
| S-EPMC3049478 | biostudies-literature